ATE549013T1 - Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren - Google Patents

Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Info

Publication number
ATE549013T1
ATE549013T1 AT10160099T AT10160099T ATE549013T1 AT E549013 T1 ATE549013 T1 AT E549013T1 AT 10160099 T AT10160099 T AT 10160099T AT 10160099 T AT10160099 T AT 10160099T AT E549013 T1 ATE549013 T1 AT E549013T1
Authority
AT
Austria
Prior art keywords
administration
reduced volume
glatiramer acetate
volume formulation
formulation
Prior art date
Application number
AT10160099T
Other languages
German (de)
English (en)
Inventor
Ayelet Altman
Doris Saltkill
Dalton L Tomlinson
Tomer El-Gad
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42283140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE549013(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Teva Pharma filed Critical Teva Pharma
Application granted granted Critical
Publication of ATE549013T1 publication Critical patent/ATE549013T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT10160099T 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren ATE549013T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27100909P 2009-07-15 2009-07-15
US27134009P 2009-07-20 2009-07-20
US33701110P 2010-01-29 2010-01-29

Publications (1)

Publication Number Publication Date
ATE549013T1 true ATE549013T1 (de) 2012-03-15

Family

ID=42283140

Family Applications (1)

Application Number Title Priority Date Filing Date
AT10160099T ATE549013T1 (de) 2009-07-15 2010-04-15 Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren

Country Status (19)

Country Link
US (3) US20110060279A1 (https=)
EP (2) EP2275086B1 (https=)
JP (1) JP2012533540A (https=)
AR (1) AR077484A1 (https=)
AT (1) ATE549013T1 (https=)
AU (1) AU2010273234A1 (https=)
BR (1) BR112012000878A2 (https=)
CA (1) CA2697570C (https=)
DK (1) DK2275086T3 (https=)
EA (1) EA201270167A1 (https=)
ES (1) ES2383347T3 (https=)
HR (1) HRP20120349T1 (https=)
IL (1) IL217240A0 (https=)
MX (1) MX2012000687A (https=)
PL (1) PL2275086T3 (https=)
PT (1) PT2275086E (https=)
RS (1) RS52367B (https=)
WO (1) WO2011008274A2 (https=)
ZA (1) ZA201200586B (https=)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
US12097357B2 (en) 2008-09-15 2024-09-24 West Pharma. Services IL, Ltd. Stabilized pen injector
CA2697570C (en) * 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
NZ598661A (en) 2009-08-20 2013-02-22 Yeda Res & Dev Low frequency glatiramer acetate therapy
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
CA2814500A1 (en) 2010-10-11 2012-04-19 Teva Pharmaceutical Industries Ltd Cytokine biomarkers as predictive biomarkers of clinical response for glatiramer acetate
HK1200274A1 (en) 2011-10-10 2015-08-07 Teva Pharmaceutical Industries Ltd. Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate
CN104684603B (zh) * 2012-08-20 2017-11-24 卡贝欧洲有限公司 自动注射装置
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014128079A1 (en) * 2013-02-19 2014-08-28 Synthon B.V. Glatiramer acetate multidose formulation
PE20151577A1 (es) * 2013-03-08 2015-11-19 Teva Pharma Dispositivo inyector reutilizable para jeringa
US8591463B1 (en) 2013-03-08 2013-11-26 Teva Pharmaceutical Industries Ltd. Re-useable injector device for syringe
BR112015021548A2 (pt) * 2013-03-08 2017-07-18 Teva Pharmaceutical Industries Ltd dispositivo injetor reutilizável para seringa
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
EP3110375B1 (en) 2014-02-26 2022-01-26 Allergan, Inc. Intraocular implant delivery apparatus
US9415176B1 (en) 2015-01-22 2016-08-16 West Pharmaceutical Services, Inc. Autoinjector having an end-of-dose visual indicator
US9155775B1 (en) * 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
CN109982712A (zh) 2016-08-31 2019-07-05 Mapi医药公司 包含醋酸格拉替雷的储库系统
EP3534893A1 (en) * 2016-11-02 2019-09-11 To Pharmaceuticals LLC Combination therapy of cbd and copaxone
WO2018106945A1 (en) 2016-12-07 2018-06-14 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
CN110382052A (zh) 2017-03-26 2019-10-25 Mapi医药公司 用于治疗进展型形式的多发性硬化症的格拉替雷储库系统
WO2019002228A1 (en) 2017-06-26 2019-01-03 Institut Pasteur TREATMENTS TO REMOVE HIV RESERVOIRS AND REDUCE VIRAL LOAD
US20200306516A1 (en) 2017-08-14 2020-10-01 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with glatiramer or a pharmaceutically acceptable salt thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2017924B3 (es) * 1985-10-11 1991-03-16 Duphar Int Res B V Inyector automatico.
NL8701091A (nl) * 1987-05-08 1988-12-01 Spruyt Hillen Bv Injectiepen.
US5981485A (en) * 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
GB8926825D0 (en) * 1989-11-28 1990-01-17 Glaxo Group Ltd Device
IL113812A (en) * 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6454746B1 (en) * 1997-06-04 2002-09-24 Eli Lilly And Company Medication delivery apparatus
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
SE518981C2 (sv) 2000-12-14 2002-12-17 Shl Medical Ab Autoinjektor
AU2003275895B2 (en) * 2002-11-25 2009-02-05 Tecpharma Licensing Ag Auto-injector comprising a resettable releasing safety device
JP2007507541A (ja) * 2003-10-03 2007-03-29 ベイヒル セラピューティクス インコーポレーティッド 修飾型の規則正しいペプチドによる脱髄性自己免疫性疾患の治療方法
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
EP1796710A4 (en) * 2004-09-02 2010-05-26 Teva Pharma THERAPY COMBINED WITH GLATIRAMER ACETATE AND N-ACETYLCYSTEINE TO TREAT MULTIPLE SCLEROSIS
HRP20160455T1 (hr) * 2004-09-09 2016-07-15 Yeda Research And Development Co., Ltd. Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
AR052321A1 (es) * 2004-10-29 2007-03-14 Sandoz Ag Procesos para la preparacion de un polipeptido
WO2007081975A2 (en) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Method of treating multiple sclerosis
US20070161960A1 (en) * 2006-01-12 2007-07-12 Fu-Yuan Li Lancet device
US20080118553A1 (en) * 2006-06-12 2008-05-22 Anton Frenkel Tannate salt form of polypeptide mixtures, their preparation and use
MX2008016335A (es) * 2006-06-30 2009-01-21 Abbott Biotech Ltd Dispositivo automatico de inyeccion.
USD622374S1 (en) * 2006-09-06 2010-08-24 Abbott Biotechnology Ltd. Automatic injection device
CA2702437C (en) * 2007-11-28 2013-06-25 Teva Pharmaceutical Industries Ltd. Method of delaying the onset of clinically definite multiple sclerosis
USD607558S1 (en) * 2008-09-19 2010-01-05 Becton Dickinson France S.A.S. Medicine injector
CA2697570C (en) 2009-07-15 2011-11-01 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration

Also Published As

Publication number Publication date
US20110066112A1 (en) 2011-03-17
BR112012000878A2 (pt) 2019-09-24
HRP20120349T1 (hr) 2012-07-31
WO2011008274A2 (en) 2011-01-20
US9018170B2 (en) 2015-04-28
WO2011008274A4 (en) 2011-11-10
AU2010273234A1 (en) 2012-02-23
DK2275086T3 (da) 2012-07-09
EP2453907A2 (en) 2012-05-23
CA2697570C (en) 2011-11-01
US20110060279A1 (en) 2011-03-10
IL217240A0 (en) 2012-02-29
HK1152249A1 (en) 2012-02-24
US7855176B1 (en) 2010-12-21
ZA201200586B (en) 2013-10-30
EP2275086B1 (en) 2012-03-14
WO2011008274A3 (en) 2011-09-22
ES2383347T3 (es) 2012-06-20
PL2275086T3 (pl) 2012-09-28
AR077484A1 (es) 2011-08-31
RS52367B (sr) 2012-12-31
JP2012533540A (ja) 2012-12-27
EP2275086A1 (en) 2011-01-19
MX2012000687A (es) 2012-09-07
PT2275086E (pt) 2012-05-18
EA201270167A1 (ru) 2012-08-30
CA2697570A1 (en) 2010-06-22

Similar Documents

Publication Publication Date Title
ATE549013T1 (de) Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
HUS1900031I1 (hu) Hatóanyagok légúti beadása
ES2618221T8 (es) Dispositivo de administración de prótesis vascular y método de uso
FI20135146L (fi) Farmaseuttiset koostumukset ja hoitomenetelmät
IL250259A0 (en) Compositions comprising ursolic acid and derivatives thereof and uses thereof
IL230786A0 (en) Heterocyclic derivative and pharmaceutical drug
EP2888265A4 (en) BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC PROCEDURES THEREWITH
PT2780022T (pt) Preparações farmacêuticas de células epr humanas e suas utilizações
LT2603232T (lt) Stabilios linaklotido vaisto formos
IL215497B (en) Oxadiazole derivatives and pharmaceutical compositions containing them
DK2529756T3 (da) Risperidon- og/eller paliperidon-implantatformulering
HUE054922T2 (hu) Riszperidon és/vagy Paliperidon implantátum készítmény
DK2493531T4 (da) Lægemiddelfremføringsindretninger og fremgangsmåde til samling
BR112015011111A2 (pt) proteína multifuncional e formulação farmacêutica
BR112012003286A2 (pt) formulações farmacêuticas contra o mau uso dos medicamentos
EP2547328A4 (en) CCR7 LIGANDEN ADMINISTRATION AND CO-ADMINISTRATION IN AN IMMUNOTHERAPY
GB201104473D0 (en) Improved pharmaceutical compositions and methods of delivery
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
EP2408912A4 (en) FOXM1 PEPTIDES AND VACCINES CONTAINING THEM
IL235768A0 (en) Pharmaceutical compositions and treatment of mastitis
FI20135152L (fi) Farmaseuttinen yhdistelmäkoostumus ja menetelmiä diabeteksen ja metabolisten sairauksien hoidossa
IL254446A0 (en) Implantable drug delivery preparations and treatment methods thereof
PL2568980T3 (pl) Pasożytobójcze preparaty lewamizolu i laktonów makrocyklicznych do wstrzykiwania
SI2525789T1 (sl) Farmacevtske formulacije naproksena za enkapsulacijo v mehko želatino in njihove kombinacije
BR112013034066A2 (pt) método de administração e tratamento